Treatment of ovarian cancer: new strategies

被引:53
作者
DiSaia, PJ
Bloss, JD
机构
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Univ Calif Irvine, Ctr Med, Chao Family Clin Canc Res Ctr, Div Gynecol Oncol,Dept Obstet & Gynecol, Orange, CA 92868 USA
关键词
ovarian cancer; gene therapy; tumor suppressor genes; oncogenes; suicide genes; immunotherapy; signal transduction inhibitors; angiogenesis;
D O I
10.1016/S0090-8258(03)00341-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives. The objective was to review the progress made in gene- and molecular-based management of ovarian cancer over the past decade and the future direction of targeted therapies. Methods. Research studies, review articles, and scientific meeting abstracts published between 1994 and 2002 were reviewed and analyzed. Results. Significant progress has been made in understanding the molecular biology of ovarian cancer and the role that single-nucleotide polymorphisms, tumor suppressor genes, and oncogenes play in promoting tumor cell growth and proliferation. Strategies have been developed to correct gene defects or single out ovarian cancer cells for destruction. Molecular-based therapies are now under development to specifically target receptors and signal transduction pathways that control cell proliferation and apoptosis, angiogenesis, cellular adhesion, and cell motility in ovarian tumors. Conclusions. The end product of this intense investigation will be new targeted therapies that offer the hope of improving the medical management of ovarian cancer while being significantly less toxic to normal cells. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:S24 / S32
页数:9
相关论文
共 48 条
  • [1] Ovarian and papillary-serous peritoneal carcinoma: Pilot study with thalidomide
    Abramson, N
    Stokes, PK
    Luke, M
    Marks, AR
    Harris, JM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (04) : 1147 - 1149
  • [2] Adenoviral-mediated suicide gene therapy for ovarian cancer
    Alvarez, RD
    Gomez-Navarro, J
    Wang, MH
    Barnes, MN
    Strong, TV
    Arani, RB
    Arafat, W
    Hughes, JV
    Siegal, GP
    Curiel, DT
    [J]. MOLECULAR THERAPY, 2000, 2 (05) : 524 - 530
  • [3] [Anonymous], 2002, CLIN GYNECOLOGIC ONC
  • [4] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types
    Baselga, J
    Rischin, D
    Ranson, M
    Calvert, H
    Raymond, E
    Kieback, DG
    Kaye, SB
    Gianni, L
    Harris, A
    Bjork, T
    Averbuch, SD
    Feyereislova, A
    Swaisland, H
    Rojo, F
    Albanell, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) : 4292 - 4302
  • [5] BERCHUCK A, 1994, AM J OBSTET GYNECOL, V170, P246
  • [6] Developmental chemotherapy in advanced ovarian cancer: Incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182)
    Bookman, MA
    [J]. SEMINARS IN ONCOLOGY, 2002, 29 (01) : 20 - 31
  • [7] TARGETED ERADICATION OF OVARIAN-CANCER MEDIATED BY INTRACELLULAR EXPRESSION OF ANTI-ERBB-2 SINGLE-CHAIN ANTIBODY
    DESHANE, J
    CABRERA, G
    GRIM, JE
    SIEGAL, GP
    PIKE, J
    ALVAREZ, RD
    CURIEL, DT
    [J]. GYNECOLOGIC ONCOLOGY, 1995, 59 (01) : 8 - 14
  • [8] Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients
    Ferrandina, G
    Lauriola, L
    Zannoni, GF
    Fagotti, A
    Fanfani, F
    Legge, F
    Maggiano, N
    Gessi, M
    Mancuso, S
    Ranelletti, FO
    Scambia, G
    [J]. ANNALS OF ONCOLOGY, 2002, 13 (08) : 1205 - 1211
  • [9] FINKLER N, 2001, P 37 ANN M AM SOC CL
  • [10] FOE R, 1994, NAT IMMUN, V13, P65